After 18 months of intravenous administration of lecanemab (Leqembi), patients may now transition to subcutaneous delivery using the Leqembi Iqlik autoinjector.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-subcutaneous-lecanemab-maintenance-dosing-early-ad-2025a1000n3r?src=rss
Author :
Publish date : 2025-09-02 14:05:00
Copyright for syndicated content belongs to the linked Source.
